[{"id":"607bb9b9-82b9-4367-a752-246843270b43","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998394","created_at":"2025-06-07T14:48:05.185Z","updated_at":"2025-06-07T14:48:05.185Z","phase":"Phase 2","brief_title":"A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer","source_id_and_acronym":"NCT06998394","lead_sponsor":"Xiangbo Wan","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/12/2025","start_date":" 03/12/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-05-31"},{"id":"18709fb5-d496-4979-9052-5f591bc2f04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949033","created_at":"2025-06-28T16:10:58.051Z","updated_at":"2025-06-28T16:10:58.051Z","phase":"Phase 3","brief_title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06949033","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 668","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-29"},{"id":"043f12c0-ede0-42eb-a459-538026133635","acronym":"","url":"https://clinicaltrials.gov/study/NCT06946836","created_at":"2025-09-07T01:24:52.108Z","updated_at":"2025-09-07T01:24:52.108Z","phase":"Phase 2","brief_title":"Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study","source_id_and_acronym":"NCT06946836","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/21/2025","start_date":" 04/21/2025","primary_txt":" Primary completion: 05/01/2031","primary_completion_date":" 05/01/2031","study_txt":" Completion: 05/11/2031","study_completion_date":" 05/11/2031","last_update_posted":"2025-04-27"},{"id":"af8b0fde-0cd4-4b0c-bf7d-ca9f737f567b","acronym":"AK104-IIT-019","url":"https://clinicaltrials.gov/study/NCT05587374","created_at":"2025-02-25T19:03:11.402Z","updated_at":"2025-02-25T19:03:11.402Z","phase":"Phase 3","brief_title":"Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)","source_id_and_acronym":"NCT05587374 - AK104-IIT-019","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Kaitanni (cadonilimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-01-23"},{"id":"358678b3-c9a6-4c23-828d-5c45b7da8cf5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06553781","created_at":"2025-02-27T08:07:07.607Z","updated_at":"2025-02-27T08:07:07.607Z","phase":"","brief_title":"A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma","source_id_and_acronym":"NCT06553781","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-08-14"},{"id":"7ae24087-c472-4aeb-9770-168fd262ba6d","acronym":"DAB","url":"https://clinicaltrials.gov/study/NCT06540729","created_at":"2025-02-25T19:17:09.926Z","updated_at":"2025-02-25T19:17:09.926Z","phase":"Phase 2","brief_title":"Disitamab Vedotin (RC48) in Combination With AK104 (PD-1/CTLA-4 Bispecific) and Bevacizumab for the Treatment of Recurrent and Persistent Clear Cell Ovarian Cancer: a Single-arm, Phase II, Multicenter Study (DAB OCC Study)","source_id_and_acronym":"NCT06540729 - DAB","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 07/31/2024","start_date":" 07/31/2024","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2024-08-06"},{"id":"356e3601-303f-449c-86cb-daf647b519de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532539","created_at":"2025-02-25T16:28:03.858Z","updated_at":"2025-02-25T16:28:03.858Z","phase":"Phase 2","brief_title":"Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma","source_id_and_acronym":"NCT06532539","lead_sponsor":"Shandong Cancer Hospital and Institute","biomarkers":" CD8 • PD-1 • TIGIT • NCAM1 • STING • CD68 • PVR","pipe":"","alterations":" ","tags":["CD8 • PD-1 • TIGIT • NCAM1 • STING • CD68 • PVR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/13/2024","start_date":" 06/13/2024","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-08-01"},{"id":"72596fa1-a0d4-4a25-9d18-6edd6d556738","acronym":"","url":"https://clinicaltrials.gov/study/NCT05505825","created_at":"2024-03-25T18:36:13.170Z","updated_at":"2024-07-02T16:35:01.060Z","phase":"Phase 1/2","brief_title":"A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT05505825","lead_sponsor":"Akeso","biomarkers":" ATRX","pipe":" | ","alterations":" ATRX mutation","tags":["ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab) • Auraza (chiauranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2022","start_date":" 08/26/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-24"},{"id":"bb3388a6-c68f-4390-9eb5-73b17cf37c28","acronym":"","url":"https://clinicaltrials.gov/study/NCT04647344","created_at":"2021-01-19T20:39:51.926Z","updated_at":"2024-07-02T16:35:07.502Z","phase":"Phase 1/2","brief_title":"A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04647344","lead_sponsor":"Akeso","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pemetrexed • Kaitanni (cadonilimab)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-04-25"},{"id":"2a7e1b59-835a-4e99-a8e3-f032d1fbcea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06341660","created_at":"2024-04-02T19:41:50.555Z","updated_at":"2024-07-02T16:35:12.061Z","phase":"Phase 2","brief_title":"To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT06341660","lead_sponsor":"Guangzhou Institute of Respiratory Disease","biomarkers":" STK11","pipe":"","alterations":" ","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/25/2023","start_date":" 05/25/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-04-02"},{"id":"2d710c27-775a-4a1c-8ecc-66ce86c200a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06331650","created_at":"2024-03-26T16:40:01.835Z","updated_at":"2024-07-02T16:35:12.792Z","phase":"Phase 2","brief_title":"A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer","source_id_and_acronym":"NCT06331650","lead_sponsor":"Guangzhou Institute of Respiratory Disease","biomarkers":" STK11","pipe":"","alterations":" ","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/09/2023","start_date":" 08/09/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-03-26"},{"id":"09d1fbdf-77a8-4bee-80bb-3ea81998914c","acronym":"EC-CRT-006","url":"https://clinicaltrials.gov/study/NCT06143748","created_at":"2023-11-22T20:17:12.091Z","updated_at":"2024-07-02T16:35:15.112Z","phase":"Phase 2","brief_title":"Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)","source_id_and_acronym":"NCT06143748 - EC-CRT-006","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD8 • CTLA4 • NCAM1 • CD68","pipe":"","alterations":" ","tags":["CD8 • CTLA4 • NCAM1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/02/2024","start_date":" 03/02/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-12"},{"id":"42b0d29c-97d2-4f83-b224-17d79727461c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06289751","created_at":"2024-03-04T19:34:55.917Z","updated_at":"2024-07-02T16:35:16.655Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer","source_id_and_acronym":"NCT06289751","lead_sponsor":"Tongji Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-03-04"},{"id":"19860fdf-02a4-4370-b31e-ec3ea23c19b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05980689","created_at":"2023-08-08T14:08:24.812Z","updated_at":"2024-07-02T16:35:20.606Z","phase":"Phase 2","brief_title":"Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT05980689","lead_sponsor":"Sun Yat-sen University","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 10/24/2023","start_date":" 10/24/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-02-07"},{"id":"9af2f6bc-a549-4c5f-a485-f12c6df2bd81","acronym":"CBC","url":"https://clinicaltrials.gov/study/NCT05812534","created_at":"2023-04-13T14:03:28.434Z","updated_at":"2024-07-02T16:35:28.805Z","phase":"Phase 2","brief_title":"Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases","source_id_and_acronym":"NCT05812534 - CBC","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" EGFR","pipe":" | ","alterations":" ALK negative","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-11-18"},{"id":"62cd6d9a-ddce-4be4-a530-2b10e968f047","acronym":"","url":"https://clinicaltrials.gov/study/NCT05839470","created_at":"2023-05-03T15:04:28.294Z","updated_at":"2024-07-02T16:35:29.204Z","phase":"Phase 2","brief_title":"Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer","source_id_and_acronym":"NCT05839470","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Kaitanni (cadonilimab) • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/19/2023","start_date":" 11/19/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-11-15"},{"id":"f2d002f5-98a4-4a25-bd34-0a02d794198c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06118645","created_at":"2023-11-07T20:13:29.678Z","updated_at":"2024-07-02T16:35:30.359Z","phase":"Phase 2","brief_title":"Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance","source_id_and_acronym":"NCT06118645","lead_sponsor":"China Medical University, China","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-11-06"},{"id":"c9214eb2-4428-4a5e-866e-3f98517eeb9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06074484","created_at":"2023-10-10T14:11:52.528Z","updated_at":"2024-07-02T16:35:34.157Z","phase":"Phase 2","brief_title":"A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT06074484","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/10/2023","start_date":" 09/10/2023","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2025","study_completion_date":" 08/10/2025","last_update_posted":"2023-10-10"},{"id":"f8beb39f-22d1-4bc0-8c73-5790f2f0aa80","acronym":"","url":"https://clinicaltrials.gov/study/NCT05808608","created_at":"2023-04-11T14:03:45.332Z","updated_at":"2024-07-02T16:35:35.848Z","phase":"Phase 1/2","brief_title":"A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma","source_id_and_acronym":"NCT05808608","lead_sponsor":"Hao Zeng","biomarkers":" TFE3","pipe":"","alterations":" ","tags":["TFE3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-25"},{"id":"2532835c-0559-458e-aa3e-12e17e900443","acronym":"NCCCNRHNSCC","url":"https://clinicaltrials.gov/study/NCT06023875","created_at":"2023-09-05T18:12:37.523Z","updated_at":"2024-07-02T16:35:38.097Z","phase":"Phase 2","brief_title":"Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06023875 - NCCCNRHNSCC","lead_sponsor":"Xuekui Liu","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • docetaxel • albumin-bound paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-05"},{"id":"32590e6e-a94d-4040-85bc-3abc38e505cb","acronym":"ACHELOUS","url":"https://clinicaltrials.gov/study/NCT06001151","created_at":"2023-08-21T15:09:07.384Z","updated_at":"2024-07-02T16:35:39.656Z","phase":"Phase 2","brief_title":"Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative","source_id_and_acronym":"NCT06001151 - ACHELOUS","lead_sponsor":"Qian Chu","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" EGFR L858R • ALK rearrangement • ROS1 fusion","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • ALK rearrangement • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2023-08-21"},{"id":"56f7d267-5341-4da2-91ed-476dd19c6e7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05994001","created_at":"2023-08-16T16:08:13.991Z","updated_at":"2024-07-02T16:35:39.843Z","phase":"Phase 1/2","brief_title":"Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody","source_id_and_acronym":"NCT05994001","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" CLDN18 • PD-1 • CTLA4","pipe":"","alterations":" ","tags":["CLDN18 • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-08-16"},{"id":"ccaf8030-3bfa-4766-a947-102f05d814ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05990127","created_at":"2023-08-14T14:10:22.252Z","updated_at":"2024-07-02T16:35:40.063Z","phase":"Phase 3","brief_title":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS \u003c 1% Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05990127","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 642","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 11/28/2026","study_completion_date":" 11/28/2026","last_update_posted":"2023-08-14"},{"id":"6b97b78a-76b3-43cb-b21f-ba6ec4f71d70","acronym":"","url":"https://clinicaltrials.gov/study/NCT05947201","created_at":"2023-07-17T14:08:37.240Z","updated_at":"2024-07-02T16:35:40.599Z","phase":"Phase 2","brief_title":"Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT05947201","lead_sponsor":"Weijia Fang, MD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • albumin-bound paclitaxel • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-08-08"}]